In summary, our findings indicate that Panobinostat may serve as a promising therapeutic strategy for prostate cancer by inhibiting HDAC3, enhancing H3K27 acetylation in the LHPP promoter region to augment its transcription, and stabilizing LHPP protein through the modulation of its acetylation and ubiquitination. This evidence concerns the gene HDAC3 and prostate cancer.